Special Issue

MYC Oncogene in Cancer: Cancer Cell Intrinsic and Immune Inhibitory Functions

Message from the Guest Editors

The MYC oncogene is a critical driver of tumorigenesis, regulating diverse processes essential for cancer cell survival, proliferation, and metabolic reprogramming. Its intrinsic oncogenic functions enable uncontrolled cellular growth, promoting genetic instability and resistance to apoptosis. Beyond these cell-autonomous effects, MYC plays a pivotal role in shaping the tumor microenvironment by exerting immune-inhibitory effects. MYC-driven cancers exploit mechanisms such as immunosuppressive cytokine secretion, recruitment of regulatory immune cells, and modulation of antigen presentation to evade immune surveillance. This duality of MYC function highlights its significance as both a driver of intrinsic oncogenic pathways and a regulator of the immune landscape in cancer. Therapeutic strategies targeting MYC, including indirect inhibition and immune modulators, represent promising approaches to disrupt its multifaceted role in tumor progression.
Understanding the interplay between MYC's oncogenic and immune-regulatory functions is essential for developing targeted therapies to mitigate its oncogenic potential.

Guest Editors

Dr. Wadie Mahauad Fernandez
Sutro Biopharma, Inc., South San Francisco, CA, USA

Dr. Konstantinos V. Floros
VCU School of Dentistry, Virginia Commonwealth University, Richmond, VA, USA

Deadline for manuscript submissions

28 February 2026

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/229195

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)